Evaluation of Software Enhancements to the Respironics BiPAP Auto Servo Ventilation (AutoSV) Device

Completed · Not applicable

Conditions studied: Sleep Disordered Breathing, Sleep Apnea, Central

In brief

This study is being undertaken to collect data from Respironics Inc's BiPAP Auto Servo Ventilation 3 (autoSV3) and compare with data from Respironics, Inc's BiPAP autoSV2, to confirm that the algorithms in the BiPAP autoSV3 device can safely and effectively treat participants experiencing Complex Sleep Apneas (Comp SAS) no worse than its predecessor, the BiPAP auto Servo ventilation 2 (autoSV2) device. This will be determined using a comparative, randomized design with the participants blinded to the therapy. Additionally, attempts will be made to blind the central scorer(s) with respect to which device is in use.

Key facts

Study ID

NCT00720213

Run by

Philips Respironics

People needed

44

Starts

2008-08-01

Expected to finish

2009-07-01

Last updated by the study team

2019-01-29

Who can join

Age: 21 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Pre-Study Inclusion Criteria:
• Age 21-80
• Ability to provide consent
• Documentation of medical stability by investigator
• Enrollment Inclusion Criteria:
• Participants who, during the ambulatory polysomnography (PSG) study (Stardust), or in lab Diagnostic PSG demonstrated an Apnea Hypopnea Index (AHI) ≥10 or Central Apnea Index (CAI) ≥5
• or
• Participants who previously demonstrated Central sleep Apnea (CSA), with a CAI≥5 on Continuous Positive Airway Pressure (CPAP) titration.

You may not qualify if…

• • Participants who are acutely ill, medically complicated or who are medically unstable.
• Pregnancy (will confirm absence of pregnancy with a urine or serum pregnancy test in women of child bearing potential).
• Participants in whom PAP therapy is otherwise medically contraindicated.
• Participants who are unwilling to wear CPAP
• Participants who are currently prescribed nocturnal oxygen use and are unable to forego oxygen during study nights.
• Participants with previously diagnosed respiratory failure or respiratory insufficiency and who are known to have chronically elevated arterial carbon dioxide levels while awake (PaCO2 ≥ 45mmHg).
• Participants who have had surgery of the upper airway, nose, sinus, or middle ear within the previous 90 days.
• Participants with untreated, non- Obstructive Sleep Apnea (OSA)/CSA sleep disorders, including but not limited to; insomnia, periodic limb movement syndrome, or restless legs syndrome (PLM Arousal Index > 15).
• Participants who are unwilling to participate in the study.

Where it is running

• University of Arizona — Tucson, Arizona, United States
• Arkansas Center for Sleep Medicine — Little Rock, Arkansas, United States
• Mark G. Goetting — Portage, Michigan, United States
• Ohio State University — Columbus, Ohio, United States
• Sleepcare Diagnostics — Mason, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.